Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Argenx Se ( (ARGX) ) has shared an update.
On January 12, 2026, argenx reported preliminary 2025 global product net sales of $4.15 billion, a 90% year-on-year increase driven by VYVGART, which is now used by roughly 19,000 patients worldwide, and outlined a 2026 plan centered on expanding VYVGART’s use and label, advancing its FcRn franchise, and accelerating its broader immunology pipeline. The company highlighted a pivotal year ahead with four registrational readouts in 2026, including the first Phase 3 data for its C2 antibody empasiprubart, multiple Phase 3 milestones across myasthenia gravis, ITP and rheumatology, and the planned start of additional registrational and early-stage studies that together position argenx for potential new product launches from 2027 onward; it also flagged an upcoming leadership transition, with COO Karen Massey set to become CEO and current CEO Tim Van Hauwermeiren moving to non-executive chairman, underscoring both operational momentum and a managed governance handover for investors and patients.
The most recent analyst rating on (ARGX) stock is a Buy with a $1091.00 price target. To see the full list of analyst forecasts on Argenx Se stock, see the ARGX Stock Forecast page.
Spark’s Take on ARGX Stock
According to Spark, TipRanks’ AI Analyst, ARGX is a Outperform.
Argenx Se’s strong financial performance and bullish technical indicators are the primary drivers of its high stock score. The company’s robust revenue growth and strategic advancements in its pipeline are significant positives. However, the high valuation and operational challenges in cash flow generation slightly temper the overall score.
To see Spark’s full report on ARGX stock, click here.
More about Argenx Se
argenx SE is a global immunology company listed on Euronext and Nasdaq that develops precision biologic therapies for severe autoimmune diseases. Its lead product, VYVGART (efgartigimod), an FcRn-targeting antibody fragment, is approved for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy worldwide and for primary immune thrombocytopenia in Japan, with a growing global footprint that now includes Latin America through argenx Brazil. The company is advancing a diversified pipeline that includes multiple FcRn-based molecules and first-in-class antibodies targeting pathways such as complement C2, MuSK, IL‑6 and IgA, with the long-term goal of securing 10 labeled indications and treating 50,000 patients globally by 2030.
Average Trading Volume: 348,484
Technical Sentiment Signal: Buy
Current Market Cap: $50.04B
See more insights into ARGX stock on TipRanks’ Stock Analysis page.